Prot #CKAZ954A12101: A Phase I/IB, Open-label, Multi-Center, Study of KAZ954 as a Single Agent and in Combination With Spartalizumab, NZV930 and NIR178 in Patients with Advanced Solid Tumors

Project: Research project

Project Details

StatusActive
Effective start/end date11/1/1912/31/22

Funding

  • Novartis Pharmaceuticals Corporation (Prot #CKAZ954A12101)